Hormonal
Bariatric surgery resolves obesity-associated gonadal dysfunction (PCOS in women, MOSH in men) in the vast majority of severely obese patients, with resolution rates of 96% for PCOS and 87% for MOSH.
If you are severely obese and have been diagnosed with PCOS or Male Obesity-Associated Secondary Hypogonadism (MOSH), bariatric surgery is the most effective treatment for resolving these conditions. Unlike diet or medication which often only manage symptoms, surgery addresses the underlying metabolic drivers, leading to resolution in nearly all women with PCOS and most men with MOSH. Consult a bariatric specialist to see if you are a candidate.
After bariatric surgery, resolution of PCOS was found in 96% (95CI 89–100) of affected women and resolution of MOSH occurred in 87% (95CI 76–95) of affected men.
Why this rating
Systematic review and meta-analysis of 29 studies with quality assessment.
Source
Prevalence of ‘obesity-associated gonadal dysfunction’ in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis
Héctor F. Escobar‐Morreale et al. · Human Reproduction Update · 2017
DOI 10.1093/humupd/dmx012
More from this paper
- Bariatric surgery reverses the sex-specific hormonal imbalances caused by obesity: it increases testosterone in men and decreases testosterone in women, while increasing SHBG and decreasing estradiol in both.Strong
- Obesity-associated gonadal dysfunction is highly prevalent in severely obese patients, affecting 36% of women (PCOS) and 64% of men (MOSH).Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →